Low Dose Naltrexone (LDN) is emerging as a promising option for reducing appetite and supporting behavioral change. Learn how it works within medically supervised wellness plans.
Naltrexone is an FDA-approved medication for opioid and alcohol dependence at standard doses of 50 mg. However, Low Dose Naltrexone (0.5 to 4.5 mg) is used off-label in research and clinical settings for its distinct effects on the immune system, opioid receptors, and inflammatory pathways.
While LDN is not FDA-approved for weight loss or obesity treatment, emerging studies suggest that its impact on reward mechanisms and inflammation may play a supportive role in appetite regulation and metabolic wellness when used as part of a medically supervised plan.
LDN works by temporarily modulating opioid receptors, leading to a rebound increase in endorphins and enkephalins, the body’s natural feel-good neurotransmitters. These chemicals are known to influence:
By supporting healthy endorphin function, LDN may help individuals manage:
Clinical observations have reported that individuals using LDN experience fewer episodes of emotional eating and improved eating behavior consistency, though more research is needed to confirm these findings.
Chronic inflammation is often associated with metabolic challenges, including impaired insulin sensitivity and dysregulated appetite signals. Several studies have shown that LDN can reduce pro-inflammatory cytokines and modulate immune responses, which may:
While LDN does not directly cause fat loss, these mechanisms may create more favorable conditions for metabolic health, which plays a role in weight management.
In clinical practice, prescribers may consider including LDN as part of a broader wellness approach for individuals who experience:
When combined with approaches like GLP-1 medications (such as semaglutide), metformin, balanced nutrition, physical activity, and behavioral counseling, LDN may help reinforce healthy appetite regulation and support long-term adherence to wellness plans.
Important: LDN is not a standalone weight-loss medication. Its role is to support the behavioral and neurochemical environment that facilitates successful weight management.
Always consult your prescribing clinician for personalized dosing and monitoring.
Low Dose Naltrexone is a promising option within the landscape of behavioral and metabolic health support. While not a treatment for obesity, its mechanisms such as endorphin modulation, appetite regulation, and inflammation reduction may help address some of the behavioral and physiological barriers to successful weight management.
When included in a clinician-supervised wellness plan alongside nutrition, movement, and other medical interventions, LDN may help individuals achieve greater consistency in appetite control and behavioral change.
This article discusses off-label use of naltrexone at low doses. The FDA has not approved LDN for weight loss, obesity, or appetite control. All usage should be under the care of a qualified healthcare provider.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
LDN may promote balance in the brain’s opioid and dopamine systems, supporting the natural pathways that regulate cravings, satiety, and emotional eating behaviors.
Some people report changes in appetite and cravings within 1–2 weeks, with more sustained behavioral shifts developing over 4–6 weeks of consistent use.
Yes. LDN is often used alongside GLP-1 receptor agonists, metformin, or bupropion as part of integrated medical plans, under the supervision of a healthcare provider.
No. Naltrexone is classified as an opioid antagonist and has no known addictive properties at any dose.
Most users do not experience sedation. Some report improved emotional stability or reduced food-related compulsions, though side effects like vivid dreams can occur initially.
Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734
(While the study focused on fibromyalgia, it also noted significant improvements in mood and regulation of endorphins—key mechanisms linked to appetite control.)
Ziauddeen H, Fletcher PC. Is food addiction a valid and useful concept? Obes Rev. 2013;14(1):19-28. doi:10.1111/j.1467-789X.2012.01046.x
Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci Monit. 2018;24:5779–5787. doi:10.12659/MSM.909212
